Regorafénib N-oxyde (M2) is primarily used in the field of oncology as a metabolite of the drug regorafenib. It plays a significant role in the treatment of advanced cancers, particularly colorectal cancer and gastrointestinal stromal tumors (GIST). The compound contributes to the inhibition of multiple kinase enzymes, which are involved in tumor growth, angiogenesis, and metastasis. By targeting these pathways, it helps to slow down the progression of cancer and improve patient outcomes. Additionally, its presence is monitored in pharmacokinetic studies to understand the metabolism and efficacy of regorafenib in clinical settings.